NLSP vs. ARAV, GRFS, LVTX, MYNZ, ONCSQ, PHVS, PROC, QLI, ADTX, and XCUR
Should you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Aravive (ARAV), Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), OncoSec Medical (ONCSQ), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), Aditxt (ADTX), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry.
NLS Pharmaceutics (NASDAQ:NLSP) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
35.8% of Aravive shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
NLS Pharmaceutics has a net margin of 0.00% compared to Aravive's net margin of -569.65%.
NLS Pharmaceutics has higher earnings, but lower revenue than Aravive.
NLS Pharmaceutics has a beta of -0.7, indicating that its share price is 170% less volatile than the S&P 500. Comparatively, Aravive has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.
In the previous week, NLS Pharmaceutics had 4 more articles in the media than Aravive. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 0 mentions for Aravive. NLS Pharmaceutics' average media sentiment score of 0.75 beat Aravive's score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the media.
Aravive has a consensus price target of $13.50, indicating a potential upside of 33,565.84%. Given Aravive's higher possible upside, analysts plainly believe Aravive is more favorable than NLS Pharmaceutics.
Aravive received 96 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 62.28% of users gave Aravive an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote.
Summary
Aravive beats NLS Pharmaceutics on 7 of the 12 factors compared between the two stocks.
Get NLS Pharmaceutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NLS Pharmaceutics Competitors List
Related Companies and Tools
